Novavax, Inc. (NVAX) Posts Q2 Loss of 8c/Share

Novavax, Inc. (NASDAQ: NVAX) reported Q2 EPS of ($0.08), $0.01 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $8.26 million versus the consensus estimate of $8.74 million.

"Progress in the second quarter maintained the momentum built in both the first quarter of the year and in 2013. We continue to make progress in our RSV and influenza vaccine development programs," said Stanley C. Erck, President and CEO of Novavax. "The second half of 2014 will be the most productive period in the company's history. We plan to initiate 4 clinical studies before the end of 2014; RSV maternal immunization, pediatric and elderly, as well as a seasonal influenza clinical trial. We also plan to initiate a combination RSV/seasonal influenza clinical trial in early 2015. In addition, we plan to present pre-clinical and clinical data at several important medical meetings later this year."

For earnings history and earnings-related data on Novavax, Inc. (NVAX) click here.

You May Also Be Interested In

• Bristol-Myers Squibb (BMY) stock slips despite earnings beat
• Donegal Group (DGICA) Tops Q1 EPS by 18c
• PHINIA Inc. (PHIN) Reports Q1 EPS of $1.08, provides guidance